Researchers examined the clinical utility of conventional magnetic resonance imaging lesion distribution criteria for the diagnosis of multiple sclerosis and similar disorders.
News
Researchers conducted a retrospective, longitudinal, population-based nested case-control study to examine the extent to which events prior to MS diagnosis differ according to social determinants of health.
Researchers evaluated the risk for serious infection in patients with multiple sclerosis treated with ocrelizumab.
Researchers examined the effectiveness of psychological therapies on cognitive, physical, and quality of life outcomes among people with multiple sclerosis.
Researchers compared the safety and efficacy of intravenous ocrelizumab with oral fingolimod in pediatric relapsing-remitting multiple sclerosis.
Researchers analyzed longitudinal changes in substructure brain volumes after menopause in women with multiple sclerosis.
The submission of additional analyses by Sanofi was deemed to be a major amendment to the application requiring a 3 month extension.
Researchers evaluated whether ocrelizumab is safe and effective for delaying disability progression in patients with primary progressive multiple sclerosis.
Researchers developed a machine learning-based tool to predict individualized risk for recurrent multiple sclerosis activity after disease modifying therapy discontinuation.
Investigators estimated the prevalence of sleep disorders in patients with multiple sclerosis.
Researchers evaluated whether people with multiple sclerosis receiving disease-modifying therapy first presented with infection symptoms to neurology or non-neurology providers.
Researchers examined use of disease-modifying therapies in women with multiple sclerosis during preconception, pregnancy, and postpartum.
Researchers evaluated whether a deep learning model could distinguish between autoimmune neuroinflammatory disorders based on retinal thickness.
Researchers examined the link between social deprivation and clinical trial participation among patients with multiple sclerosis in the United States and United Kingdom.
Researchers examined the association between ultraprocessed food consumption and multiple sclerosis activity in patients with a first demyelinating event.
Researchers examined the association between temperature sensitivity-related neurological symptoms and disease progression in patients with multiple sclerosis.
Researchers examined the association between levels of vitamin D and risk for MS among White and Black military personnel in the US.
Researchers assessed the real-world performance of the 2024 McDonald criteria in patients undergoing evaluation for suspected multiple sclerosis.
Researchers evaluated the long-term efficacy and safety of ublituximab in patients with multiple sclerosis over a 6-year follow-up period.
Researchers identified clinical and magnetic resonance imagining predictors of fatigue worsening in patients with multiple sclerosis.
Researchers examined the association between multiple sclerosis and risk for dementia in middle-aged and older adults.
Researchers evaluated the relationship between blood pressure measurement and disability progression in patients with multiple sclerosis.
Researchers conducted a retrospective observational study using data on 7401 neurologists prescribing MS drugs from 2015 to 2019 in the Medicare Part D database linked to the US Centers for Medicare & Medicaid Services Open Payments database.
Investigators examined the association between the breadth of formulary coverage for MS disease-modifying therapies and MS relapse in a retrospective cohort study.
Investigators examined health care use 25 years before MS symptom onset in a matched cohort study using linked clinical and administrative data.
Researchers conducted a retrospective cohort study involving 22,657 patients with a relapsing-remitting MS onset between 18 and 40 years to examine potential therapeutic inertia in women.
Investigators randomly assigned 16 female patients with MS with neurogenic overactive bladder to receive TPTNS or rTMS for a pilot study.
Researchers sought to compare the safety and efficacy of tolebrutinib vs teriflunomide in relapsing multiple sclerosis, using data from the GEMINI 1 and 2 trials.
Presenting at ACTRIMS 2025, researchers compared treatment patterns and clinical outcomes in patients with relapsing multiple sclerosis who recently started treatment with cladribine vs fingolimod, dimethyl fumarate, and teriflunomide.
In a retrospective comparative analysis, researchers assessed the long-term clinical outcomes and treatment responses to tocilizumab and rituximab in patients with aquaporin-4 IgG-seropositive NMOSD and MOGAD.
